7 Results for "

haemophilia A

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "haemophilia A" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P99283
CAS No.: 1312299-39-0
Synonyms: NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody

Target:  

Factor Xa

Research Areas:  

Others

Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
loading...
    loading...
Cat. No.: HY-114128
CAS No.: 1192451-26-5
Synonyms: NN-7088; NN 7170

Target:  

Factor VIII

Research Areas:  

Others

Turoctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa pegol can be used for researching haemophilia A .
loading...
    loading...
Cat. No.: HY-P99465
CAS No.: 2156634-62-5
Synonyms: BAY 1093884
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
loading...
    loading...
Cat. No.: HY-P99840
CAS No.: 2055206-13-6
Synonyms: CB-2679d; DalcA; ISU-304

Target:  

Inhibitory Antibodies

Research Areas:  

Others

Dalcinonacog alfa is a recombinant FIX factor that can be used in the study of Haemophilia B .
loading...
    loading...
Cat. No.: HY-112935
CAS No.: 181054-95-5
Synonyms: BAX326; Coagulation Factor IX [Recombinant]; BeneFIX

Target:  

Ser/Thr Protease

Research Areas:  

Others

Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B .
loading...
    loading...
Cat. No.: HY-P991379

Research Areas:  

Others

MG1113A is a human monoclonal antibody (mAb) targeting TFPI. MG1113A can be used in Haemophilia research.
loading...
    loading...
Cat. No.: HY-L171
4,388 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 4,388 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.